THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
John B. Harlow Appointed President and COO of Larimar Therapeutics
Reports Second Quarter 2026 Financial and Business Update
Investor Presentation
2026 Annual Meeting Results; Class III Directors Elected
Reports First Quarter 2026 Financial and Business Update
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results
Q2
FY 2025
Q3
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership